Artificial intelligence is emerging as a powerful tool for improving the diagnosis, phenotyping, and treatment of inflammatory skin diseases such as alopecia.
Regulators overseeing rare disease treatments need better tools to weigh competing risks in real time. Sarepta Therapeutics’ Elevidys is a prime example of why.
Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), joins the global ...
Prostate cancer (PCa) represents a highly heterogeneous disease that requires tools to assess oncologic risk and guide patient management and treatment planning. Current models are based on various ...
Immuto CEO Faraz Choudhury spoke with Pharmaceutical Executive about his company’s work with focusing on Surface Protein Conformations (SPCs) for target discovery. According to him, traditional target ...
Novartis’ kidney disease troika keeps marching forward. With a new FDA approval, the company’s Fabhalta has become the first treatment endorsed by the agency for the ultrarare kidney disease ...
News-Medical.Net on MSN
DeepRare AI helps shorten the rare disease diagnostic journey with evidence-linked predictions
By Tarun Sai Lomte A new AI-driven diagnostic framework combines clinical, genetic, and phenotypic data to help shorten the ...
A high-risk cohort of beneficiaries with chronic kidney disease (CKD) stage 3 have a profile similar to patients with CKD stages 4 and 5, indicating potential benefit of earlier nephrology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results